AMRXAmneal Pharmaceuticals, Inc.
$19.92+103% 1Y
$19.92
$9.6052 weeks$20.49
The financials
Amneal Pharmaceuticals, Inc. by the numbers
Amneal Pharmaceuticals, Inc. (AMRX) reported revenue of $796M in Q2 2026 (quarter ended Jun 30, 2026), up 9.9% from the same quarter a year earlier. That came with a gross margin of 42% and net income of $58M (7.2% of revenue). For the full year FY2025, revenue was $3.02B (+8.0% year on year) and net income $72M. Its largest product in Q2 2026 was Subtotal Therapeutic Classes at $149M, 19% of the disclosed total, ahead of Central Nervous System at 12%. The next results filing is expected around Oct 29, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $796M | $725M | +9.9% |
| Gross profit | $335M | $286M | +17% |
| Operating income | $130M | $111M | +17% |
| Net income | $58M | $22M | +157% |
| Diluted EPS | $0.18 | $0.07 | +157% |
| Product | Revenue | Share |
|---|---|---|
| Subtotal Therapeutic Classes | $149M | 19% |
| Central Nervous System | $95M | 12% |
| Distribution Service | $87M | 11% |
| Other Dosage Forms | $82M | 11% |
| Transdermal | $67M | 8.7% |
| Ephinephrine Auto Injector | $62M | 8.1% |
| Injectable | $57M | 7.4% |
| Government Label | $50M | 6.5% |
| Hormonal Allergy | $42M | 5.5% |
| Biosimilar | $29M | 3.8% |
| Institutional | $12M | 1.6% |
| Other Therapeutic Classes | $12M | 1.5% |
| Oral Liquid | $10M | 1.3% |
| Product And Service Other | $7.7M | 1.0% |
| International | $7.6M | 1.0% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $770.3M (+13%)
International grew +300% year on yearLicense Agreement -100% year on year
Segment Latestquarter on quarteryear on year
- Subtotal Therapeutic Classes$149.3M$149.3Mquarter on quarter +12%year on year +17%+12%+17%
- Central Nervous System$95.3M$95.3Mquarter on quarter +14%year on year +14%+14%+14%
- Distribution Service$86.9M$86.9Mquarter on quarter -2.5%year on year -13%-2.5%-13%
- Other Dosage Forms$81.6M$81.6Mquarter on quarter +75%year on year +20%+75%+20%
- Transdermal$67.0M$67.0Mquarter on quarter -9.4%year on year +65%-9.4%+65%
- Ephinephrine Auto Injector$62.2M$62.2Mquarter on quarter +48%year on year -6.6%+48%-6.6%
- Injectable$56.8M$56.8Mquarter on quarter +14%year on year +64%+14%+64%
- Government Label$50.2M$50.2Mquarter on quarter -16%year on year +11%-16%+11%
- Hormonal Allergy$42.1M$42.1Mquarter on quarter +17%year on year +19%+17%+19%
- Biosimilar$29.1M$29.1Mquarter on quarter +31%year on year +15%+31%+15%
- Institutional$12.1M$12.1Mquarter on quarter +23%year on year +20%+23%+20%
- Other Therapeutic Classes$11.9M$11.9Mquarter on quarter -15%year on year +36%-15%+36%
- Oral Liquid$10.4M$10.4Mquarter on quarter -14%year on year -42%-14%-42%
- Product And Service Other$7.7M$7.7Mquarter on quarter +9.0%year on year -1.1%+9.0%-1.1%
- International$7.6M$7.6Mquarter on quarter +43%year on year +300%+43%+300%
- License Agreement$0.00$0.00quarter on quarter n/ayear on year -100%n/a-100%
Drug Manufacturers, Specialty & Generic
Ranks #16 of 41 by RyuScore